NLS Pharma News

New Market – July 16, 2026

Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management

The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.

Collaboration – July 16, 2026

Mendus collaborates with the South Australian Health and Medical Research Institute

Mendus has signed an agreement with the South Australian Health and Medical Research Institute (SAHMRI) to support preparations for the Phase 2 VITAL-TFR2 trial with the company’s lead product vididencel in chronic myeloid leukemia (CML).

Collaboration – July 15, 2026

Navinci and Lumito initiate pilot project

Navinci Diagnostics has initiated a pilot project together with Lumito to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis.

New Market – July 14, 2026

FDA approves Leqembi Iqlik subcutaneous injection as a starting dose for early Alzheimer’s disease

BioArctic’s partner Eisai has announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik) as a starting dose for the treatment of early Alzheimer’s disease.

Agreement – July 14, 2026

AstraZeneca enters exclusive global license agreement with Dizal Pharmaceutical

AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.

Clinical Trials

Clinical Trials – July 14, 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program

Evaxion has presented new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

Biotech article – July 13, 2026

New clinical data on the Leqembi subcutaneous autoinjector presented

BioArctic’s partner Eisai has presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease.

Clinical Trials – June 30, 2026

FluoGuide announces positive results from Phase 2 trial

FluoGuide has announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer.

Clinical Trials – June 23, 2026

Elicera receives positive feedback from Swedish MPA on clinical study in Grade IV Glioma

Elicera Therapeutics held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company’s iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.

Clinical Trials – June 18, 2026

Cantargia starts new investigator-initiated lung cancer prevention study

Cantargia has reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer.

Clinical Trials – June 15, 2026

Immunovia announces new performance data

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

Clinical Trials – June 15, 2026

SynAct announces positive Phase 2b results

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Clinical Trials – June 11, 2026

Evaxion presents new preclinical data

Evaxion announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

Clinical Trials – June 8, 2026

Pharmability submits clinical trial application for first-in-human Phase Ib study

Pharmability has announced the submission of a Clinical Trial Application (CTA) for TIR-C, the company’s lead drug candidate for atopic dermatitis (eczema).

Clinical Trials – May 25, 2026

Sobi announces positive Phase 3 results

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Profiles in Pharma

Profiles in Pharma – April 2, 2025

The Jalkanens: A shared thirst for knowledge

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Profiles in Pharma – November 1, 2023

Jonina Gudmundsdottir, Coripharma

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

Profiles in Pharma – July 3, 2023

Deborah Dunsire

The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years ago, and the ability to transform lives still drives her to this day. For more than 100 years, Lundbeck has been at the forefront of […]

Profiles in Pharma – October 1, 2021

Malin Parkler – Passionate about science, health & leadership

Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people […]

Profiles in Pharma – August 15, 2019

Katarina Ageborg, CEO AstraZeneca Sweden

Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new CEO, prefers not to think about being center stage, but instead about what her position can do for the company, Sweden and the pharmaceutical industry as a whole. “I don’t think about it that way […]

Profiles in Pharma – July 1, 2017

Embracing diversity – for the sake of true innovation

Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]

Profiles in Pharma – March 22, 2017

“The scientist in me wants to make a difference”

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market. What made you take the leap to go on your […]

Profiles in Pharma – March 8, 2017

“We have to embrace the new era of diabetes care”

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Profiles in Pharma – February 16, 2017

From regulator to pharma industry specialist

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Profiles in Pharma – April 21, 2014

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]